Andrew P. Combs

6.4k citations

65 papers · 3.9k indexed · 2 hit papers · h-index 25

Impact in

Biological Psychiatry top 1%
- Tryptophan and brain disorders
Organic Chemistry top 0.5%
- Multicomponent Synthesis of Heterocycles
- Catalytic C–H Functionalization Methods
- Catalytic Cross-Coupling Reactions
- Synthesis and biological activity
- Sulfur-Based Synthesis Techniques

Papers in

Biological Psychiatry 4
Toxicology 4
- Bioactive Compounds and Antitumor Agents 4

Co-authors: S. David Brown Thomas A. Keating Paul Tempest Robert W. Armstrong Patrick Y. S. Lam Simon Saubern Charles G. Clark Michael P. Winters
Journals: Cancer Research (11 papers)Journal of Biological Chemistry (5 papers)Journal of Medicinal Chemistry (5 papers)Tetrahedron Letters (4 papers)Organic Letters (4 papers)
Partner nations: United States Russia Germany

In The Last Decade

Andrew P. Combs

63 papers receiving 3.8k citations

Hit Papers

align trajectories log scale

New aryl/heteroaryl CN bond cross-coupling reactions via arylboronic acid/cupric acetate arylation 1998 · 893 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1998 Tetrahedron Letters
1996 Accounts of Chemical Research

Peers

Countries citing papers authored by Andrew P. Combs

Since Specialization

Citations

This map shows the geographic impact of Andrew P. Combs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Combs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Combs more than expected).

Fields of papers citing papers by Andrew P. Combs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Combs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Combs. The network helps show where Andrew P. Combs may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew P. Combs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew P. Combs Line = papers co-authored together Andrew P. Combs links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs Blood ·幸秀林, 葛莺, 智律秋山, 敬子的野, Caroline Vance O'Keefe, Ian Johnson, Neha Bhagwat, Yue Zou, Arpita Mondal, В.П. Решетило, 奈美神埜, Chun Chen, Corey H. Basch, Noel R. Wardwell, Sang‐Hyun Lee, Mayra Chicaiza-Flores, Andrew P. Combs, Peggy Scherle	2025	0
2	167 (PB155): Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload that safely achieve maximal and tumor specific degradation and efficacy in mouse models European Journal of Cancer ·John Carter, Arvind Agarwal, Sivakumar Manickam, Mygre Lopes da Silva, Jennifer Park, KC Luk, Roger S. Holmes, Julia E. Rager, Neil Stahl, Jacques Côté, Andrew Crossan, Chen Chen, Fotios Christos A. Kafantaris, Min Wang, Luiz Alberto de Oliveira Ribeiro, Sang‐Hyun Lee, Andrew P. Combs, Peggy Scherle, Noel R. Wardwell, Koichi Ito	2024	2
3	Abstract 6270: Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers Cancer Research ·Zhihan Niu, Valéria Cristina Almeida de Azevedo Barbosa, A. Badenes, Dorofeev MIu, Kris Vaddi, Andrew P. Combs, Koichi Ito, Peggy Scherle	2023	1
4	Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans Drug Metabolism and Disposition ·Jan Paul de Boer, W. Green, A.E.J.M. Tellings, Karen J. Bowman, JALT CALL SIG, Nikol Kitić, Frank M. Nedza, William E. Frietze, Laurine G. Galya, Andrew P. Combs, Swamy Yeleswaram, Vidushi Vatsa	2016	34
5	Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Carolyn D. Dzierba, Thais M. Sielecki, Argyrios G. Arvanitis, 陶世荃 TAO Shi-Quan, Xing Rong-g, Amy Takvorian, Maria Rafalski, José Parejo Fernández, I Gusti Ayu Janiantari, 公洋山本, Ge Zhang, Thaddeus F. Molski, Harvey Wong, Robert Zaczek, Nicholas J. Lodge, Andrew P. Combs, Paul J. Gilligan, George L. Trainor, Joanne J. Bronson, John E. Macor	2012	5
6	INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support Neoplasia ·Jun Li, Margaret Favata, Mary Elizabeth Piercy, Eian Caulder, Beth Ann Thomas, Xiaoming Wen, Richard Sparks, Yasuka Shimajiri, Z. Lochmann, Andrew P. Combs, Kris Vaddi, Kimberly A. Solomon, Peggy Scherle, Robert Newton, Jordan S. Fridman	2010	62
7	Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity Clinical Cancer Research ·Phillip C.C. Liu, Eian Caulder, Jun Li, Paul Waeltz, Jens Daum, Richard Wynn, Cigdem Urku, Yanlong Li, Erin L. Crowgey, Gregory Hollis, Patrick J. Haley, Richard Sparks, Andrew P. Combs, James D. Rodgers, Timothy C. Burn, Kris Vaddi, Jordan S. Fridman	2009	15
8	Abstract #2848: Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia Cancer Research ·Jordan S. Fridman, Eian Caulder, Xiaoming Wen, James D. Rodgers, Andrew P. Combs, Timothy C. Burn, Kris Vaddi	2009	1
9	Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model Journal of Medicinal Chemistry ·Eddy W. Yue, Brent Douty, Brian Wayland, Michael J. Bower, Xiangdong Liu, Lynn Leffet, Qian Wang, Kevin Bowman, Michael Hansbury, Changnian Liu, Min Wei, Yanlong Li, Richard Wynn, Timothy C. Burn, Holly K. Koblish, Jordan S. Fridman, Brian Metcalf, Peggy Scherle, Andrew P. Combs	2009	187
10	Selective JAK inhibition proves efficacious in epithelial cancer models Journal of Clinical Oncology ·Krishna Vaddi, Eian Caulder, Rupert Breitwieser, 伊边, Jerzy K. Kowalski, Jesper Sjöberg, Andrew P. Combs, Jeanloup Sieff, Steven Friedman, Jordan S. Fridman	2008	1
11	Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines Bioorganic & Medicinal Chemistry Letters ·Brent Douty, Brian Wayland, J. Paul, Michael J. Bower, James R. Pruitt, Lori L. Bostrom, Min Wei, Ronald M. Klabe, Lucie Gonneville, Richard Wynn, Timothy C. Burn, Phillip C.C. Liu, Andrew P. Combs, Eddy W. Yue	2007	55
12	Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B Journal of Biological Chemistry ·J. Paul, Lucie Gonneville, Milton C. Hillman, Cigdem Urku, Eddy W. Yue, Brent Douty, Brian Wayland, Padmaja Polam, Matthew L. Crawley, Erin McLaughlin, Richard Sparks, Brian Glass, Amy Takvorian, Andrew P. Combs, Timothy C. Burn, Gregory Hollis, Richard Wynn	2006	55
13	Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors Bioorganic & Medicinal Chemistry Letters ·Lorin A. Thompson, Ann Y. Liauw, C. X. Yu, José Parejo Fernández, Stephen E. Mercer, Thomas Maduskuie, Marcie A. Glicksman, Arthur Roach, Jere E. Meredith, Rui‐Qin Liu, Andrew P. Combs, Jeffrey N. Higaki, Barbara Cordell, Dietmar Seiffert, Robert Zaczek, David W. Robertson, Richard E. Olson	2006	14
14	Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics Journal of Biological Chemistry ·J. Paul, Lucie Gonneville, Milton C. Hillman, Cigdem Urku, Min Wei, Brian G. Reid, Ronald M. Klabe, Eddy W. Yue, Brian Wayland, Brent Douty, Padmaja Polam, Zelda R. Wasserman, Michael J. Bower, Andrew P. Combs, Timothy C. Burn, Gregory Hollis, Richard Wynn	2006	61
15	Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure–activity relationships of a peptide scaffold Bioorganic & Medicinal Chemistry ·Eddy W. Yue, Brian Wayland, Brent Douty, Matthew L. Crawley, Erin McLaughlin, Amy Takvorian, Zelda R. Wasserman, Michael J. Bower, Min Wei, Yanlong Li, J. Paul, Lucie Gonneville, Richard Wynn, Timothy C. Burn, Phillip C.C. Liu, Andrew P. Combs	2006	44
16	Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors Bioorganic & Medicinal Chemistry Letters ·Richard Sparks, Padmaja Polam, Wenyu Zhu, Matthew L. Crawley, Amy Takvorian, Erin McLaughlin, Min Wei, J. Paul, Lucie Gonneville, Nancy J. Taylor, Yanlong Li, Richard Wynn, Timothy C. Burn, Phillip C.C. Liu, Andrew P. Combs	2006	49
17	Novel Inhibition of Porcine Pepsin by a Substituted Piperidine Journal of Biological Chemistry ·Jovita Marcinkeviciene, Lisa M. Kopcho, Tao Yang, Robert A. Copeland, Brian Glass, Andrew P. Combs, Nikoo Falahatpisheh, Lorin A. Thompson	2002	9
18	Mechanism of Inhibition of β-Site Amyloid Precursor Protein-cleaving Enzyme (BACE) by a Statine-based Peptide Journal of Biological Chemistry ·Jovita Marcinkeviciene, Ying Luo, Nilsa Graciani, Andrew P. Combs, Robert A. Copeland	2001	32
19	Helicobacter pylori-selective Antibacterials Based on Inhibition of Pyrimidine Biosynthesis Journal of Biological Chemistry ·Robert A. Copeland, Jovita Marcinkeviciene, Tasir S. Haque, Lisa M. Kopcho, Wenjun Jiang, Kathy Wang, Hemlata Raut, Christine Sizemore, Thao D.P. Tran, Lori Foster, Seifu Tadesse, Andrew P. Combs, Andrew M. Stern, George L. Trainor, Andrew Slee, Michael J. Rogers, Frank W. Hobbs	2000	56
20	Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis Chemistry & Biology ·Sibo Feng, Tarun M. Kapoor, Fumiyuki Shirai, Andrew P. Combs, Stuart L. Schreiber	1996	46

About Andrew P. Combs

Andrew P. Combs is a scholar working on Biological Psychiatry, Toxicology, Behavioral Neuroscience, Organic Chemistry and Genetics, having authored 65 papers that have together received 3.9k indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (12 papers), Protein Tyrosine Phosphatases (10 papers), Catalytic Cross-Coupling Reactions (7 papers), Cytokine Signaling Pathways and Interactions (7 papers), Protein Degradation and Inhibitors (6 papers), Microwave-Assisted Synthesis and Applications (5 papers), Carbohydrate Chemistry and Synthesis (5 papers) and Bioactive Compounds and Antitumor Agents (4 papers). The work is most often cited by research in Biological Psychiatry (320 citations), Organic Chemistry (2.4k citations), Toxicology (162 citations), Behavioral Neuroscience (96 citations) and Molecular Biology (1.7k citations). Andrew P. Combs has collaborated with scholars based in United States, Russia and Germany. Frequent co-authors include S. David Brown, Thomas A. Keating, Paul Tempest, Robert W. Armstrong, Patrick Y. S. Lam, Simon Saubern, Charles G. Clark, Michael P. Winters, Dominic M. T. Chan and Richard Sparks. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Journal of Medicinal Chemistry, Tetrahedron Letters and Organic Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact